Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 537 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2015  |  Volume : 19  |  Issue : 2  |  Page : 309

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus

Baby Memorial Hospital, Kozhikode, Kerala, India

Date of Web Publication14-Jan-2015

Correspondence Address:
Joe George
Baby Memorial Hospital, Kozhikode, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.149334

Rights and Permissions

How to cite this article:
George J. Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus. Indian J Endocr Metab 2015;19:309

How to cite this URL:
George J. Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus. Indian J Endocr Metab [serial online] 2015 [cited 2021 Jan 22];19:309. Available from: https://www.ijem.in/text.asp?2015/19/2/309/149334


The combination of Metformin and Sulfonylurea is a well-studied therapy, which addresses both underlying defects of type 2 diabetes mellitus (T2DM) that is, insulin deficiency and insulin resistance. [1]

Of the available low dose glimepiride (0.5 mg, 1 mg and 2 mg) [2] based therapies, combinations with 1 mg and 2 mg of glimepiride and metformin are widely used and well accepted. Recently, we observed the effectiveness of glimepiride 0.5 mg and metformin 500 mg combination in 941 early stage T2DM patients who were followed up for a period of 3 months. There was a 24.5% reduction in fasting blood glucose (baseline: 151 mg/dl, after 3 months: 114 mg/dl), 26.5% reduction in postprandial blood glucose (baseline: 215 mg/dl, after 3 months: 158 mg/dl) and 28.2% reduction in random blood glucose (baseline: 202 mg/dl, after 3 months: 145 mg/dl). The therapy was well-tolerated, and there were no reports of hypoglycemia or weight gain.

This observation is in concordant with earlier studies that low-dose metformin-sulfonylurea combination therapy achieved a good glycemic control, caused least hypoglycemia, weight gain and gastrointestinal disturbances. [3] Thus, initiating a therapy with a combination of glimepiride 0.5 mg and metformin 500 mg can be considered suitable for the management of early stage type 2 diabetic patients, which however needs to be substantiated in future by large-scale randomized studies.

   References Top

Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108 Suppl 6a: 15S-22.  Back to cited text no. 1
Umayahara R, Yonemoto T, Kyou C, Morishita K, Ogawa T, Taguchi Y, et al. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocr J 2014.  Back to cited text no. 2
Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9.  Back to cited text no. 3


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded380    
    Comments [Add]    

Recommend this journal